European journal of pharmacology · 2025
Tedizolid for osteoarticular infections: Evaluation of the published evidence.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Athanasiou Veatriki, Ragias Dimitrios, Tzikopoulou Maria, Zenios Michalis, Falagas Matthew E
Аннотация
INTRODUCTION: Tedizolid phosphate, an oxazolidinone antibiotic, has been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). However, its off-label use has been reported in various infections, including osteoarticular infections.
METHODS: A systematic review of data from PubMed, Scopus, and Web of Science was conducted to evaluate the antimicrobial activity, safety, and effectiveness of tedizolid in patients with bone and joint infections, including prosthetic joint infections, osteomyelitis, and septic arthritis. The review encompassed clinical trials, prospective and retrospective studies, and case reports.
RESULTS: A total of 6 in vitro antimicrobial and 15 clinical studies were included in the review. Tedizolid demonstrated high antimicrobial activity across all in vitro studies. In 106 patients from the included clinical studies, tedizolid showed high effectiveness, with therapy success ranging from 76.5 % to 100 % in 4 cohort studies. Additionally, favorable outcomes were reported in 7 of 9 case reports. Tedizolid exhibited a favorable safety profile, with 11 of 15 clinical studies reporting no adverse events in 37 patients. Adverse events leading to therapy discontinuation were observed in 9 out of 124 patients included in the remaining studies.
CONCLUSION: The current appraisal suggests that tedizolid is a promising antibiotic for the treatment of bone and joint infections. Nonetheless, its use should be reserved for multi-drug resistant infections when other approved therapeutic options are limited. Further clinical studies are warranted to substantiate the effectiveness and safety of tedizolid in this patient population.
METHODS: A systematic review of data from PubMed, Scopus, and Web of Science was conducted to evaluate the antimicrobial activity, safety, and effectiveness of tedizolid in patients with bone and joint infections, including prosthetic joint infections, osteomyelitis, and septic arthritis. The review encompassed clinical trials, prospective and retrospective studies, and case reports.
RESULTS: A total of 6 in vitro antimicrobial and 15 clinical studies were included in the review. Tedizolid demonstrated high antimicrobial activity across all in vitro studies. In 106 patients from the included clinical studies, tedizolid showed high effectiveness, with therapy success ranging from 76.5 % to 100 % in 4 cohort studies. Additionally, favorable outcomes were reported in 7 of 9 case reports. Tedizolid exhibited a favorable safety profile, with 11 of 15 clinical studies reporting no adverse events in 37 patients. Adverse events leading to therapy discontinuation were observed in 9 out of 124 patients included in the remaining studies.
CONCLUSION: The current appraisal suggests that tedizolid is a promising antibiotic for the treatment of bone and joint infections. Nonetheless, its use should be reserved for multi-drug resistant infections when other approved therapeutic options are limited. Further clinical studies are warranted to substantiate the effectiveness and safety of tedizolid in this patient population.